Marshall Wace’s Nuvation Bio NUVB Stock Holding History

Marshall Wace’s Portfolio NUVB Stock Details NUVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$474K	Sell	83,402 -20,144	-19%	-$98.5K	﹤0.01%	2547
2026 Q1	$444K	Sell	103,546 -1,130,727	-92%	-$6.3M	﹤0.01%	2500
2025 Q4	$11.1M	Buy	1,234,273 +1,024,274	+488%	+$6.34M	0.01%	834
2025 Q3	$777K	Sell	209,999 -661,191	-76%	-$1.8M	﹤0.01%	2049
2025 Q2	$1.7M	Buy	+871,190	New	+$1.81M	﹤0.01%	1639
2023 Q4	–	Sell	-29,111	Closed	-$39K	–	2478
2023 Q3	$39K	Hold	29,111	–	–	﹤0.01%	2097
2023 Q2	$52.4K	Hold	29,111	–	–	﹤0.01%	2370
2023 Q1	$48.3K	Hold	29,111	–	–	﹤0.01%	2546
2022 Q4	$55.9K	Hold	29,111	–	–	﹤0.01%	2834
2022 Q3	$65K	Hold	29,111	–	–	﹤0.01%	3223
2022 Q2	$94K	Buy	+29,111	New	+$127K	﹤0.01%	3286
2021 Q3	–	Sell	-95,043	Closed	-$885K	–	3298
2021 Q2	$885K	Buy	+95,043	New	+$1.08M	﹤0.01%	1878

Other funds holding NUVB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Marshall Wace's NUVB Position: Q2 2026 in Review

Marshall Wace reduced its Nuvation Bio (NUVB) stake by 19% in Q2 2026, selling an estimated $98.5K and leaving 83,402 shares worth $474K. The position accounts for ﹤0.01% of the portfolio, ranked #2547.

Marshall Wace first reported a position in NUVB in Q2 2021 and has held it in 12 quarters since. The position peaked at $11.1M in Q4 2025. 244 funds tracked by Wall St. Rank hold NUVB as of Q2 2026.

Marshall Wace held 83,402 shares of Nuvation Bio worth $474K as of Q2 2026.
Marshall Wace sold 20,144 Nuvation Bio shares in Q2 2026, an estimated $98.5K.
Nuvation Bio made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2547 holding.
Marshall Wace first reported a position in Nuvation Bio in Q2 2021 and has held it in 12 quarters since.
Marshall Wace's Nuvation Bio position peaked at $11.1M in Q4 2025.
244 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.